Hypertonic Saline to Reduce Hospital Admissions in Bronchiolitis

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (331 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: hourshospitalof 17to determinepresence of
  Phrases that lowered it: inhaledrespiratorytermtracter
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Collaborators: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 65.9% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: triple (raises risk) · Design
• Drug's FAERS reports with a death: 8.4% (lowers risk) · Drug's FDA history
• Minimum age: not given (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 25 (lowers risk) · Sponsor's track record
• Maximum age: 2 (raises risk) · Who can join
• Responsible party: principal investigator (lowers risk) · Design
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports before start: 16181 (raises risk) · Drug's FDA history
• Disease area, infectious disease: Yes (lowers risk) · Disease area
• Sponsor's past trials: 30 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis NCT01777347 · started 2012 · scored riskier than 48% of active trials completed
• The Effectiveness of Nebulized Hypertonic Saline Solution for Acute Bronchiolitis NCT02760719 · started 2015 · scored riskier than 11% of active trials terminated
• High Flow Therapy vs Hypertonic Saline in Bronchiolitis NCT01873144 · started 2010 · scored riskier than 39% of active trials completed
• Nebulised 3% Hypertonic Saline in Infants With Acute Bronchiolitis NCT06558461 · started 2022 · scored riskier than 17% of active trials completed
• Nebulized Hypertonic Saline for Bronchiolitis NCT00619918 · started 2008 · scored riskier than 8% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.